Lilly hires Denali executive to run neuroscience divisionnews2025-11-07T14:02:21+00:00November 7th, 2025|Endpoints News|
Eisai plots label expansion for subcutaneous Leqembi, details early launch progressnews2025-11-06T20:26:42+00:00November 6th, 2025|Endpoints News|
FDA approves J&J’s Darzalex for smoldering multiple myelomanews2025-11-06T20:20:50+00:00November 6th, 2025|Endpoints News|
Updated: Trump lands sweeping cost cuts on Lilly, Novo weight loss drugsnews2025-11-06T17:04:00+00:00November 6th, 2025|Endpoints News|
Novo Nordisk raises Metsera bid again, hoping to top Pfizer’s latest offernews2025-11-06T15:56:47+00:00November 6th, 2025|Endpoints News|
#ASN25: Vera outlines full Phase 3 win for kidney drug, preps for FDA filing by year’s endnews2025-11-06T15:11:58+00:00November 6th, 2025|Endpoints News|
J&J’s Caplyta approved by FDA as add-on treatment for depressionnews2025-11-06T14:20:11+00:00November 6th, 2025|Endpoints News|
Low vaccine uptake hampers Moderna earnings, including meager RSV salesnews2025-11-06T12:00:52+00:00November 6th, 2025|Endpoints News|
AstraZeneca reports record-breaking quarter, says it can ‘absorb impact’ of US pricing dealnews2025-11-06T11:54:41+00:00November 6th, 2025|Endpoints News|
Lilly’s amylin moves to Phase 3 after success in next obesity drug wavenews2025-11-06T11:45:50+00:00November 6th, 2025|Endpoints News|
